J&J's Imbruvica delivers solid response in relapsed CLL; Teva teams with Eagle to market new cancer med;

> Johnson & Johnson ($JNJ) unveiled positive results for Imbruvica in a small trial in high-risk leukemia patients; patients had failed on other therapies, but 88% responded to the J&J drug. Story

> Teva Pharmaceutical ($TEVA) signed up to promote an as-yet-to-be-approved cancer drug from Eagle Pharmaceuticals in the U.S.; EP-3102 is a potential rival to Teva's own Treanda. Article

> A U.S. judge said he would weigh other False Claims Act court decisions and consider reviving an off-label marketing case against Bayer Pharma. Report (reg. req.)

> Teva Pharmaceutical rolled out its generic versions of two injectable drugs, the blood thinner Lovenox and antibiotic Zyvox. News

> Bayer's Stivarga will lead the pack of new colon cancer drugs in China, GlobalData analysts say, with peak sales of $291 million in that market. More

And Finally... Roche ($RHHBY) is teaming up with Qualcomm ($QCOM) on remote health monitoring to gather patient data and help it track treatment results. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.